Latest 10-K annual reports

NYSE
Rockwell Automation's fiscal year 2025 saw a 1% sales increase and 7% Adjusted EPS growth, but reported net income and diluted EPS declined due to significant impairment and asbestos-related charges.
OTC.Pink
EvoAir Holdings Inc. reported a significant net loss of $14.97 million for fiscal year 2025, despite a reduction in operating expenses, as revenue declined by 9.5% and the company continues to operate with a substantial working capital deficit.
OTC.Pink
Rivulet Entertainment, Inc. filed an amendment to its transition report to clarify that it is not a shell company, alongside standard management certifications.
NASDAQ
Comtech Telecommunications Corp. reports significant operational and financial improvements in fiscal 2025, removing substantial doubt about its ability to continue as a going concern, driven by increased liquidity and strategic debt reduction.
OID
MGT Capital Investments, Inc. reported a net income of $5.521 million for 2024, primarily due to non-operating gains, despite ceasing all revenue-generating operations and receiving a going concern warning from its auditors.
NYSE
TE Connectivity plc announced an 8.9% increase in net sales for fiscal 2025, driven by robust performance in Industrial Solutions and strategic acquisitions, despite a decline in net income due to tax adjustments.
NYSE
Emerson Electric Co. reported a 3% increase in net sales to $18.0 billion and a 41% rise in net earnings from continuing operations to $2.285 billion for fiscal year 2025, driven by strategic acquisitions and operational efficiencies.
NYSE
Franklin Resources reports a 1% decrease in AUM to $1.66 trillion for fiscal year 2025, with a 13% rise in net income despite significant fixed income outflows.
NYSE
Tyson Foods reported a 2.1% sales growth to $54.4 billion in fiscal 2025, but operating income declined significantly due to substantial legal contingency accruals and goodwill impairments.
NYSE
Organon & Co. filed an amended annual report disclosing an internal investigation into improper Nexplanon sales practices and material weaknesses in internal controls, leading to executive changes.
AMEX
AMCON Distributing Company reported a significant decrease in net income for fiscal year 2025 to $0.6 million, down from $4.3 million in fiscal 2024, despite increased sales driven by acquisitions and price adjustments.
NASDAQ
Skyworks Solutions, Inc. reported a 2.2% decrease in fiscal year 2025 net revenue to $4.08 billion, alongside a significant proposed merger with Qorvo valued at $22.0 billion, expected to close in early 2027.
NYSE
Fair Isaac Corporation (FICO) announced robust financial results for fiscal year 2025, driven by significant revenue increases in its Scores segment and continued expansion of its FICO Platform.
NYSE
Visa Inc. reported an 11% increase in net revenue and 14% non-GAAP diluted EPS growth for fiscal year 2025, driven by payments volume and processed transactions, while navigating significant litigation accruals.
NASDAQ
Village Super Market, Inc. filed an amendment to its annual report to include previously omitted exhibits and a new incentive-based compensation recovery policy.
NYSE
Skillz Inc. reported a net loss of $46.8 million in 2024, a 39% revenue decrease, amidst strategic shifts towards profitability and ongoing legal challenges.
NASDAQ
Rave Restaurant Group, Inc. filed an amendment to its annual report to include a new policy for recovering excessive incentive-based compensation from executive officers.
NASDAQ
Kura Sushi USA reported a significant reduction in net loss for fiscal year 2025, driven by robust sales growth from new restaurant openings and strategic menu pricing, despite a decline in comparable restaurant sales.
NASDAQ
Qualcomm announced a 14% increase in fiscal 2025 revenues to $44.3 billion, but net income fell 45% to $5.5 billion due to a significant $5.7 billion tax charge related to new U.S. tax legislation.
NASDAQ
DevvStream Corp. reported a significant net loss of $12.07 million for fiscal year 2025, alongside a new digital asset treasury strategy and ongoing liquidity challenges.
NYSE
NCR Atleos Corporation has identified a material weakness in internal control over financial reporting, leading to a restatement of prior financial statements, despite reporting increased revenue and Adjusted EBITDA for 2024.
OTC.Pink
NaturalShrimp Incorporated has ceased all business operations following the court-approved sale of substantially all its assets to creditors Streeterville Capital and Bucktown Capital for a $35.7 million credit bid and $100,000 cash.
NASDAQ
CHSCP
Chs INC
CHS Inc. reported a significant decline in fiscal 2025 net income to $597.9 million from $1.1 billion in the prior year, driven by softening commodity margins and planned refinery maintenance.
OID
The company's latest 10-K filing details solid financial performance, strategic acquisitions, and ongoing operational efficiencies.
AMEX
PEDEVCO Corp. amends its 2024 annual report to correct accounting errors, reporting increased production and net income despite ongoing operational challenges and a note default.
OQB
T-REX Acquisition Corp. reported a significant increase in net losses and a working capital deficit for fiscal year 2025, compounded by a facility foreclosure action and operational disruptions.
NASDAQ
Apple Inc. reports robust fiscal year 2025 results driven by significant growth in Services and iPhone Pro models, despite challenges in Greater China and Wearables, while navigating increasing legal and regulatory pressures.
Thumzup Media Corporation filed an amendment to its 2024 annual report, detailing significant increases in executive and director compensation, including substantial stock option grants tied to uplisting and performance milestones.
NASDAQ
PriceSmart, Inc. announced robust financial results for fiscal year 2025, driven by increased sales, membership growth, and strategic investments in technology and new club locations, alongside plans for expansion into Chile.
NYSE
Rafael Holdings reported a reduced net loss for fiscal year 2025, driven by the Cyclo merger and R&D efforts, while advancing its lead drug candidate Trappsol Cyclo for NPC1.